ATE296821T1 - Triarylimidazol-derivate als cytokin-inhibitoren - Google Patents
Triarylimidazol-derivate als cytokin-inhibitorenInfo
- Publication number
- ATE296821T1 ATE296821T1 AT01915488T AT01915488T ATE296821T1 AT E296821 T1 ATE296821 T1 AT E296821T1 AT 01915488 T AT01915488 T AT 01915488T AT 01915488 T AT01915488 T AT 01915488T AT E296821 T1 ATE296821 T1 AT E296821T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- cytokine inhibitors
- triarylimidazole
- derivatives
- triarylimidazole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0007405.4A GB0007405D0 (en) | 2000-03-27 | 2000-03-27 | Compounds |
PCT/GB2001/001314 WO2001072737A1 (en) | 2000-03-27 | 2001-03-26 | Triarylimidazole derivatives as cytokine inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE296821T1 true ATE296821T1 (de) | 2005-06-15 |
Family
ID=9888509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01915488T ATE296821T1 (de) | 2000-03-27 | 2001-03-26 | Triarylimidazol-derivate als cytokin-inhibitoren |
Country Status (9)
Country | Link |
---|---|
US (1) | US6906089B2 (de) |
EP (1) | EP1268465B1 (de) |
JP (1) | JP2003528870A (de) |
AT (1) | ATE296821T1 (de) |
AU (1) | AU4257901A (de) |
CO (1) | CO5280078A1 (de) |
DE (1) | DE60111205D1 (de) |
GB (1) | GB0007405D0 (de) |
WO (1) | WO2001072737A1 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002225730A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
ES2291455T3 (es) | 2001-03-12 | 2008-03-01 | Avanir Pharmaceuticals | Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular. |
CN1951939A (zh) | 2001-05-24 | 2007-04-25 | 伊莱利利公司 | 作为药物的新的吡唑衍生物 |
GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
GB0217783D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
JP2005539000A (ja) * | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 |
EP1554272B1 (de) | 2002-08-09 | 2006-10-25 | Eli Lilly And Company | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
OA12925A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
MXPA05002982A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf). |
BR0314302A (pt) | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
JP4547271B2 (ja) * | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物 |
AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
JP2006506366A (ja) * | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
JP2006217801A (ja) * | 2003-01-15 | 2006-08-24 | Kirin Brewery Co Ltd | TGFβ阻害活性を有する化合物の新規用途 |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
CN1826111A (zh) * | 2003-04-10 | 2006-08-30 | 阿文尼尔药品公司 | 用于治疗变应性和过增生性疾病的咪唑衍生物 |
TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
WO2005085241A1 (ja) | 2004-03-05 | 2005-09-15 | Taisho Pharmaceutical Co., Ltd. | チアゾール誘導体 |
US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
EP1771171A1 (de) * | 2004-07-29 | 2007-04-11 | Schering-Plough Ltd. | Verwendung von alk-5-hemmern zur modulation bzw. hemmung der myostatinaktivität zur verstärkung von magergewebe bei tieren |
ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
EP2152093A4 (de) * | 2007-05-04 | 2011-05-25 | Jana Pickova | Verbundfutter für aquakulturen |
LT2170396T (lt) | 2007-08-03 | 2017-03-10 | Summit (Oxford) Limited | Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
TWI436767B (zh) * | 2008-03-14 | 2014-05-11 | Otsuka Pharma Co Ltd | 基質金屬蛋白酶-2(mmp-2)及/或基質金屬蛋白酶-9(mmp-9)抑制劑 |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
CN102015686B (zh) * | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
EP2476672A1 (de) | 2010-12-22 | 2012-07-18 | Momentive Specialty Chemicals Research Belgium S.A. | Glycidylester von alpha,alpha-verzweigten Säurezusammensetzungen |
CN103764655B (zh) | 2011-07-13 | 2017-04-12 | Sk化学公司 | 作为alk5和/或alk4抑制剂的经2‑吡啶基取代的咪唑 |
AU2013267422B2 (en) | 2012-05-30 | 2018-07-26 | Cornell University | Generation of functional and durable endothelial cells from human amniotic fluid-derived cells |
RS60318B1 (sr) | 2012-08-01 | 2020-07-31 | Ikaika Therapeutics Llc | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela |
US20140242595A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
AU2019396360A1 (en) | 2018-12-11 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors |
AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
TW202132297A (zh) | 2019-11-22 | 2021-09-01 | 美商施萬生物製藥研發Ip有限責任公司 | 經取代吡啶及使用方法 |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
BR112023000592A2 (pt) | 2020-07-15 | 2023-01-31 | Chiesi Farm Spa | Derivados de pirido oxazina amino como inibidores de alk5 |
MX2023000521A (es) | 2020-07-15 | 2023-02-13 | Chiesi Farm Spa | Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). |
US20240116948A1 (en) | 2020-12-23 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
TW202328102A (zh) | 2021-09-21 | 2023-07-16 | 義大利商吉斯藥品公司 | 作為alk5抑制劑之嗒𠯤基胺基衍生物 |
WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH561202A5 (de) * | 1971-05-10 | 1975-04-30 | Ciba Geigy Ag | |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5955480A (en) * | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
JPH11180958A (ja) * | 1997-12-24 | 1999-07-06 | Yamanouchi Pharmaceut Co Ltd | 新規アミン誘導体 |
EP1169317B1 (de) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazole |
-
2000
- 2000-03-27 GB GBGB0007405.4A patent/GB0007405D0/en not_active Ceased
-
2001
- 2001-03-26 WO PCT/GB2001/001314 patent/WO2001072737A1/en active IP Right Grant
- 2001-03-26 EP EP01915488A patent/EP1268465B1/de not_active Expired - Lifetime
- 2001-03-26 DE DE60111205T patent/DE60111205D1/de not_active Expired - Lifetime
- 2001-03-26 US US10/239,815 patent/US6906089B2/en not_active Expired - Fee Related
- 2001-03-26 JP JP2001570648A patent/JP2003528870A/ja not_active Withdrawn
- 2001-03-26 AT AT01915488T patent/ATE296821T1/de not_active IP Right Cessation
- 2001-03-26 AU AU42579/01A patent/AU4257901A/en not_active Abandoned
- 2001-03-27 CO CO01024184A patent/CO5280078A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5280078A1 (es) | 2003-05-30 |
EP1268465A1 (de) | 2003-01-02 |
GB0007405D0 (en) | 2000-05-17 |
AU4257901A (en) | 2001-10-08 |
DE60111205D1 (de) | 2005-07-07 |
US6906089B2 (en) | 2005-06-14 |
US20030149277A1 (en) | 2003-08-07 |
EP1268465B1 (de) | 2005-06-01 |
WO2001072737A1 (en) | 2001-10-04 |
JP2003528870A (ja) | 2003-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE296821T1 (de) | Triarylimidazol-derivate als cytokin-inhibitoren | |
ATE231143T1 (de) | Triarylimidazole | |
MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
DK1161428T3 (da) | Pyrimidinforbindelser | |
ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
EP1340755A4 (de) | Mittel mit wirkung gegen helicobacter | |
PH12009500610A1 (en) | 4-imidazolin-2-one compounds | |
ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
ATE259813T1 (de) | Triazolopyrimidinderivate | |
WO2003031414A1 (fr) | Nouveau compose heterocyclique et agent anti-inflammatoire | |
NO20033131L (no) | Anvendelse av 2-amino-4-pyridylmetyl-tiazolinderivater som inhibitorer forinduktibel NO-syntase | |
AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
DE69619259T2 (de) | Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase | |
DE60122559D1 (de) | Indolderivate als pde5-inhibitoren | |
ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate | |
ATE348800T1 (de) | 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren | |
CA2423357A1 (en) | Fused heterocyclic derivatives as phosphodiesterase inhibitors | |
WO2002080918A1 (fr) | Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire | |
SE9901901D0 (sv) | Compounds | |
ATE374751T1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern | |
ATE364382T1 (de) | Hemmer der aggregation von polyq |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |